This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Asset-centric is a term coined by Medicxi founding partner Francesco De Rubertis to describe an investment strategy he pioneered, together with Kevin Johnson and Michele Ollier, in the early years of the 21 st Century. The key was focusing investment on a single asset to avoid the problem with pipelines in early-stage biotech companies. While it seemed superficially attractive to hedge against failure of the lead asset by having a second or a third program in the wings, the reality usually turne
Throughout history, clinical trials have been an important element in learning about new drugs and treatments — but without patient participation, the medical remedies that are so ubiquitous in our lives today would not exist. Because it’s required for all drugs to go through testing before they are released on the market, volunteers for clinical trials have a major impact on medical research as a whole.
This chart shows the pharmaceutical companies with the most patents in Ireland. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Ireland? appeared first on DrugPatentWatch - Make Better Decisions.
The biosimilar boom for provider-administered drugs continues to accelerate. Net prices in therapeutic classes with biosimilar competition have declined by 60% or more over the past few years. Some major biological reference products have now lost a majority of their unit sales to their biosimilars. As we explain below, this accelerating adoption also boosts profits for pharmaceutical wholesalers and specialty distributors—particularly when these channel participants can influence which biosimi
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Tik Tok was first released in 2016. While slow out of the starting gate with emergent media opportunities, in 2022, pharma is embracing the platform in both unbranded and branded efforts. While historically, a lot of Tik Tok use has been comprised of individuals releasing videos of them showing off dance moves and physique, the time for embracing the platform by institutional users appears has arrived.
Biologics are complex molecular entities that require extensive planning and development strategies to control development costs, ensure compliance with regulations, and speed up a product to commercialization. Hiring a biologics consultant ensures you receive expert advice and support throughout the entire CMC development process. In this article, we will outline why you should consider a biologics consulting service and what benefits this will have for your company.
Signup to get articles personalized to your interests!
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Biologics are complex molecular entities that require extensive planning and development strategies to control development costs, ensure compliance with regulations, and speed up a product to commercialization. Hiring a biologics consultant ensures you receive expert advice and support throughout the entire CMC development process. In this article, we will outline why you should consider a biologics consulting service and what benefits this will have for your company.
Annual Drug Patent Expirations for ARIKAYCE+KIT Arikayce Kit is a drug marketed by Insmed Inc and is included in one NDA. There are eleven patents protecting this drug. This drug…. The post New patent for Insmed Inc drug ARIKAYCE KIT appeared first on DrugPatentWatch - Make Better Decisions.
Today’s guest post comes from Megan Marchal, Director of Specialty Pharmacy Strategy at CoverMyMeds. Megan discusses upcoming specialty medication launches. As she explains, patients will need extra help to overcome the challenges of access, affordability, and adherence. Learn more about CoverMyMeds’ patient-centric technology solutions by downloading their Access Report: Oncology Edition.
Bispecific antibodies (BsAb) are promising biotherapeutics for an increasing range of diseases. There are currently seven BsAb approved by the U.S. Food and Drug Administration (FDA) and/or the European Medicines Agency (EMA) for a range of indications: Relapsed or refractory precursor B-cell acute lymphoblastic leukemia Bleeding due to hemophilia A Non-small cell lung cancer Unresectable or metastatic uveal melanoma Wet (neovascular) age-related macular degeneration and diabetic macular edema R
Are you ready for another round-up for our latest Clinical features and updates? This season, we have new plugins, Allergies module, even better therapeutic categories and alternatives, and much more to help you bring your offerings to the next level. Let's dive in! Conditions Search Plugin and ICD-10 Search Plugin Read More Below We’ve created ready-to-use plugins that make searching conditions and ICD-10 concepts quick and easy!
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
This chart shows the drugs with the most patents in Canada. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Canada? appeared first on DrugPatentWatch - Make Better Decisions.
Informa Connect’s Trade & Channel Strategies Summit. December 12-14, 2022 in Philadelphia, PA www.informaconnect.com/trade. Don’t miss Informa Connect's Trade & Channel Strategies Summit , coming up December 12-14, 2022 in Philadelphia! Join your colleagues from across the industry and be part of critical, solution-focused discussions designed to help optimize distribution models and channel strategies driven by market dynamics, product types, site of care and reimbursement, all delivere
The app marketplace is competitive, especially in the health and wellness sector, making user acquisition a considerable challenge. Successful app outreach requires strategic targeting and smart technology to appeal to users — and Antidote can provide these solutions. Our patient recruitment expertise translates well to assisting apps with building out their user base.
Study startup is a complicated, multi-faceted process – notoriously prone to delays due to the many stakeholders, systems, and decisions involved. One decision that can greatly impact the success and efficiency of your study is determining which sites you will partner with to conduct the study. Historically, this process has been littered with pain points and inefficiencies for both sponsors, contract research organizations (CROs), and research sites.
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Annual Drug Patent Expirations for DEXTENZA Dextenza is a drug marketed by Ocular Therapeutix and is included in one NDA. It is available from one supplier. There are three patents…. The post New patent for Ocular Therapeutix drug DEXTENZA appeared first on DrugPatentWatch - Make Better Decisions.
DrugBank’s Clinical API is a powerful tool that can be used across an array of use cases, including everything from EMR/EHR to hospice and precision medicine. We’ve intentionally built our Clinical API to connect multiple data points across unique modules as a means of delivering specific and empowering insights to the full range of our users.
Regular readers of the blog know and appreciate our focus (fixation?) on the learned intermediary rule. Not because it is fun to say and makes us feel smart. No, we follow and write on the learned intermediary rule because it is a cornerstone of the law on allegedly inadequate drug and device warnings. It holds most everywhere that a drug or device manufacturer’s duty to warn runs to the prescribing physician (the learned intermediary), not to the patient.
Annual Drug Patent Expirations for KYPROLIS Kyprolis is a drug marketed by Onyx Therap and is included in one NDA. There are eleven patents protecting this drug and three Paragraph…. The post New patent for Onyx Therap drug KYPROLIS appeared first on DrugPatentWatch - Make Better Decisions.
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Annual Drug Patent Expirations for KATERZIA Katerzia is a drug marketed by Azurity and is included in one NDA. It is available from one supplier. There are six patents protecting…. The post New patent for Azurity drug KATERZIA appeared first on DrugPatentWatch - Make Better Decisions.
Annual Drug Patent Expirations for MAKENA+PRESERVATIVE+FREE Makena Preservative Free is a drug marketed by Covis and is included in one NDA. It is available from two suppliers. The generic ingredient…. The post New patent for COVIS drug MAKENA PRESERVATIVE FREE appeared first on DrugPatentWatch - Make Better Decisions.
Annual Drug Patent Expirations for MAKENA+%28AUTOINJECTOR%29 Makena (autoinjector) is a drug marketed by Covis and is included in one NDA. It is available from two suppliers. There are ten patents…. The post New patent for COVIS drug MAKENA (AUTOINJECTOR) appeared first on DrugPatentWatch - Make Better Decisions.
Annual Drug Patent Expirations for MAKENA Makena is a drug marketed by Covis and is included in one NDA. It is available from two suppliers. There are ten patents protecting…. The post New patent for COVIS drug MAKENA appeared first on DrugPatentWatch - Make Better Decisions.
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
This chart shows the pharmaceutical companies with the most patents in France. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in France? appeared first on DrugPatentWatch - Make Better Decisions.
Annual Drug Patent Expirations for SUMAVEL+DOSEPRO Sumavel Dosepro is a drug marketed by Endo Ventures Ltd and is included in one NDA. There are nine patents protecting this drug. SUMAVEL…. The post New patent expiration for Endo Ventures drug SUMAVEL DOSEPRO appeared first on DrugPatentWatch - Make Better Decisions.
Annual Drug Patent Expirations for MOVANTIK Movantik is a drug marketed by Redhill and is included in one NDA. It is available from three suppliers. There are six patents protecting…. The post New patent expiration for Redhill drug MOVANTIK appeared first on DrugPatentWatch - Make Better Decisions.
Annual Drug Patent Expirations for SPRAVATO Spravato is a drug marketed by Janssen Pharms and is included in one NDA. It is available from one supplier. There are five patents…. The post New patent for Janssen Pharms drug SPRAVATO appeared first on DrugPatentWatch - Make Better Decisions.
Annual Drug Patent Expirations for AUSTEDO Austedo is a drug marketed by Teva Branded Pharm and is included in one NDA. It is available from one supplier. There are eight…. The post New patent for Teva Branded drug AUSTEDO appeared first on DrugPatentWatch - Make Better Decisions.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
100 
Let's personalize your content